Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has released the “Implementation Rules for the Exit Mechanism of Clinical Translation and Application of New Biomedical Technologies” (the “Rules”), aiming to standardize the management of clinical translation and application of new biomedical technologies within the Pilot Zone and clarify full‑process handling requirements for project suspension, exit and resumption — tightening the governance framework around China’s special real‑world data and advanced‑therapy sandbox.

Policy Snapshot

Core Provisions – Suspension Mechanism

• Two Suspension Pathways: Circumstances for project suspension include voluntary suspension by medical institutions and suspension ordered by regulatory authorities within a specified time limit.
• Resumption Route: Before the expiration of the suspension period, medical institutions that have completed all rectification matters and meet the required conditions may submit an application for resumption — creating a defined pathway back to operation after remediation.

Core Provisions – Exit Mechanism

• Mandatory Exit Triggers: Circumstances for mandatory project exit include major defects in technology and safety and forgery or tampering of clinical data — placing data integrity violations at the center of the enforcement framework.
• Voluntary Exit: Medical institutions may apply to the Lecheng Medical and Pharmaceutical Administration for voluntary exit from an approved project.
• Enforcement Backstop: If an institution fails to apply for voluntary exit despite meeting the project exit conditions, the Administration will initiate the mandatory exit process directly.
• Finality and Cooling‑Off: Projects shall not be resumed after exit. For mandatory exits, the responsible department of the relevant medical institution is barred for one year — from the date of the exit decision — from applying for clinical translation and application of new biomedical technologies.

Market Impact & Outlook

• Maturing Sandbox Governance: The Rules mark a shift in the Lecheng Pilot Zone from access facilitation toward lifecycle regulation — pairing its well‑known fast‑track for unapproved innovative therapies with explicit suspension, exit and resumption discipline, a structure international regulators will watch as a model for special economic medical zones.
• Data Integrity Emphasis: By treating clinical data forgery or tampering as a mandatory exit trigger with a one‑year application ban, the framework strengthens the credibility of real‑world evidence generated in the Pilot Zone — evidence increasingly used to support NMPA registrations by multinational and domestic innovators.
• Institutional Compliance Burden: Approved medical institutions must now build rectification and resumption‑readiness capabilities, raising operational compliance standards across the zone’s advanced‑therapy programs.
• Ecosystem Consolidation: The combination of irreversible exit and cooling‑off penalties is likely to deter marginal operators and concentrate Lecheng clinical translation activity among institutions with robust quality systems; implementation guidance and effective dates were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of the Rules and their impact on clinical translation and application of new biomedical technologies within the Hainan Boao Lecheng International Medical Tourism Pilot Zone. Actual outcomes may differ materially due to risks including regulatory enforcement practice, institutional compliance execution and evolving policy guidance.-Fineline Info & Tech